Diagnosing cancers of unknown primaries
Friday, 27 February, 2009
A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.
The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.
The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.
Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.
For more information, see the March/April issue of Australian Life Scientist.
Sensor's cell-like structure said to overcome key blood-testing barrier
Drawing inspiration from nature, Australian researchers have developed a sensor they believe...
Revealed — a common bacterium's role in stubborn wound infections
A team of international researchers have uncovered how a common bacterium, Enterococcus...
Depression impacts energy at a cellular level, researchers find
Depression symptoms may be rooted in fundamental changes in the way brain and blood cells use...
